HALO
HALOZYME THERAPEUTICS, INC.
Healthcare • CIK: 0001159036
Loading...
Market Cap
$6.47B
P/E (TTM)
11.6x
Rev Growth (TTM)
—
Net Margin (TTM)
47.3%
FCF Yield (TTM)
—
FCF Margin (TTM)
45.9%
Cash Flow Health
Free Cash Flow8/8 positive
TTM$541M
Q2 '25
$98M-36%
Q1 '25
$153M-13%
FCF Margin
TTM45.9%
Q2 '2530.1%-48%
Sector: 0.0%Top 10%
OCF Margin–
OCF/NI0.98x
CapEx Coverage77.3x
FCF Yield–
FCF Growth (2Y)–
Cash Conversion Cycle
–
Capital Allocation & Returns
Total Shareholder Yield
TTM0.0%
Div Yield0.0%
Insufficient data
Dividend & Payout Metrics
Dividend Yield (TTM)0.0%
Free Cash Flow (TTM)$540.7M
Stock Repurchases ()$250.0M
Est. Dividends Paid (TTM)$0
Shows how management rewards shareholders
Operational Efficiency & Returns
Return on Invested CapitalTTM
31.1%
P25MedianP75
75th pctl (med: 0.0%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
46.6%
Asset Turnover
0.56x
Leverage (1+D/E)
5.54x
D/E: 4.54x
DuPont: 145.1% ≈ 31.1% ROIC
Asset & CapEx Efficiency
Invested Cap Turn
0.67x
8Q:–
CapEx Intensity
0.4%
8Q:–
Asset-based ROIC formula
QUARTERLY TRENDS
Last 8 quarters + TTM
| Metric | TTM | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | $1.2B | $325.7M↑23.0% | $264.9M↓11.1% | $298.0M↑2.7% | $290.1M↑25.4% | $231.4M↑18.1% | $195.9M↓14.8% | $230.0M↑6.5% | $216.0M |
Operating Income | $682.7M | $202.4M↑43.0% | $141.5M↓19.4% | $175.5M↑7.5% | $163.2M↑39.2% | $117.2M↑22.7% | $95.5M↓5.4% | $101.0M↑14.4% | $88.3M |
Net Income | $557.3M | $165.2M↑39.9% | $118.1M↓13.8% | $137.0M↑0.0% | $137.0M↑46.9% | $93.2M↑21.4% | $76.8M↓10.0% | $85.4M↑4.3% | $81.8M |
Operating Cash Flow | $547.8M | $99.7M↓35.3% | $154.2M↓13.6% | $178.5M↑54.7% | $115.4M↑106.8% | $55.8M↓56.9% | $129.4M↑26.5% | $102.4M↓22.7% | $132.4M |
Free Cash Flow | $540.7M | $98.1M↓36.0% | $153.3M↓12.6% | $175.4M↑54.1% | $113.9M↑114.0% | $53.2M↓57.7% | $125.9M↑26.2% | $99.8M↓22.9% | $129.5M |
Total Equity | N/A |
Valuation Analysis
Fair Value
Price-to-EarningsTTM
11.6x
Valuation Lenses
Earnings
11.6x
vs – sector
Cash Flow
15.2x
EV/FCF vs –
Growth-Adj
–PEG
N/A
Quality-Adj
0.4P/E per %ROIC
ROIC: 31.1%
Shareholder Returns
Dividend
–
Buyback
–
Total Yield
–
Market Cap$6.47B
EV–
Multi-angle valuation analysis with sector context
Business Quality & Moat
Overall Quality Score
99/100
Exceptional
Composite score: Returns (40%) + Consistency (30%) + Earnings Quality (30%)
Returns on Capital
Return on Equity (ROE)Top 10%
1.4%
8Q:–
Return on Invested Capital (ROIC)Top 25%
31.1%
8Q:–
DuPont Analysis (ROIC = NOPAT Margin × Asset Turnover)
NOPAT Margin: 46.6%
Asset Turnover: 0.56x
Earnings Quality
Cash Conversion
0.98x
OCF / Net Income
FCF Consistency
–
Positive quarters
Competitive Moat Indicators
Pricing Power
Gross Margin84.2%
Capital Efficiency
Invested Capital Turnover0.67x
Working Capital
Cash Conversion Cycle–
Growth Quality & Momentum
Growth Rates
Revenue Growth YoY
N/A
OpInc Growth YoY
72.7%
EPS Growth YoY
N/A
FCF 3Y CAGR
N/A
Margin Quality & Sustainability
High Quality
Profitability Cascade
Gross
84.2%
Operating
57.9%
Top 25% in sector
Net
47.3%
Margins Unknown
Earnings Quality Signals
SBC / Revenue
—
FCF vs Net Gap
-1.4 pts
FCF: 45.9% | Net: 47.3%
Quality = stability + cash conversion + low dilution
Balance Sheet & Solvency
Leveraged
Net Debt / EBITDA
–Net Debt: $1.45B
Interest Coverage
–
Leverage Metrics
Debt-to-Equity
4.54x
Balance sheet risk & solvency analysis